UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000049521
Receipt number R000056304
Scientific Title Evaluation of microaneurysms using intravitreal faricimab for diabetic macular edema
Date of disclosure of the study information 2022/11/16
Last modified on 2022/11/16 10:04:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of microaneurysms using intravitreal faricimab for diabetic macular edema

Acronym

Evaluation of microaneurysms using intravitreal faricimab for diabetic macular edema

Scientific Title

Evaluation of microaneurysms using intravitreal faricimab for diabetic macular edema

Scientific Title:Acronym

Evaluation of microaneurysms using intravitreal faricimab for diabetic macular edema

Region

Japan


Condition

Condition

diabetic macular edema

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluating microaneurysms before and after treatment of farisimab in diabetic macular edema

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes in the number of microaneurysms

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who received farisimab for DME from the Department of Ophthalmology, University of Fukui Hospital between August 1, 2022 and December 31, 2024

Key exclusion criteria

Patients who refused to be enrolled in this study.
Patients who were unable to undergo ophthalmologic examination due to cognitive or physical factors.
Other cases in which the principal investigator determines that the patient is inappropriate as a research subject.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name yoshihiro
Middle name
Last name takamura

Organization

university of Fukui Hospital

Division name

Ophthalmology

Zip code

9101193

Address

23-3, matcuoka shimoaituki, eiheiji-cho, yoshida-gun, Fukui

TEL

0776-61-8403

Email

ytakamura@hotmail.com


Public contact

Name of contact person

1st name yutaka
Middle name
Last name yamada

Organization

university of Fukui Hospital

Division name

Ophthalmology

Zip code

9101193

Address

23-3, matcuoka shimoaituki, eiheiji-cho, yoshida-gun, Fukui

TEL

0776-61-8403

Homepage URL


Email

yyutaka@u-fukui.ac.jp


Sponsor or person

Institute

university of Fukui Hospital

Institute

Department

Personal name



Funding Source

Organization

self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

university of Fukui Hospital

Address

23-3, matcuoka shimoaituki, eiheiji-cho, yoshida-gun, Fukui

Tel

0776-61-8403

Email

ytakamura@hotmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 11 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2022 Year 08 Month 01 Day

Date of IRB

2022 Year 11 Month 16 Day

Anticipated trial start date

2022 Year 08 Month 01 Day

Last follow-up date

2025 Year 05 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

nothing particular


Management information

Registered date

2022 Year 11 Month 16 Day

Last modified on

2022 Year 11 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056304